{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=brivanib", "query": { "intervention": "brivanib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=brivanib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T20:51:36.693Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00207103", "title": "MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Neoplasm Metastasis" ], "interventions": [ { "name": "Brivanib", "type": "DRUG" }, { "name": "Brivanab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2004-09", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2008-11-04", "last_synced_at": "2026-09-11T20:51:36.693Z", "location_count": 3, "location_summary": "Santa Monica, California • Indianapolis, Indiana • Madison, Wisconsin", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00207103" }, { "nct_id": "NCT00594984", "title": "Phase I/II Combination With Irinotecan- Erbitux", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer (MCRC)" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Brivanib", "type": "DRUG" }, { "name": "Brivanib Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2008-05", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-09-11T20:51:36.693Z", "location_count": 4, "location_summary": "Los Angeles, California • Louisville, Kentucky • St Louis, Missouri", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00594984" }, { "nct_id": "NCT00798252", "title": "Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Ixabepilone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Brivanib alaninate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 111, "start_date": "2009-03", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2015-07-07", "last_synced_at": "2026-09-11T20:51:36.693Z", "location_count": 3, "location_summary": "Los Angeles, California • Boston, Massachusetts • Detroit, Michigan", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00798252" }, { "nct_id": "NCT00908752", "title": "Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Brivanib", "type": "DRUG" }, { "name": "Brivanib Placebo", "type": "OTHER" }, { "name": "TACE Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 734, "start_date": "2009-07-20", "completion_date": "2018-01-26", "has_results": false, "last_update_posted_date": "2019-12-02", "last_synced_at": "2026-09-11T20:51:36.693Z", "location_count": 7, "location_summary": "Los Angeles, California • San Diego, California • The Bronx, New York + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "The Bronx", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00908752" }, { "nct_id": "NCT01267253", "title": "Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Persistent Disease", "Recurrent Cervical Carcinoma" ], "interventions": [ { "name": "Brivanib Alaninate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 31, "start_date": "2011-04-04", "completion_date": "2014-02-28", "has_results": true, "last_update_posted_date": "2019-03-20", "last_synced_at": "2026-09-11T20:51:36.693Z", "location_count": 43, "location_summary": "Phoenix, Arizona • Burbank, California • San Francisco, California + 37 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01267253" }, { "nct_id": "NCT01367275", "title": "Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "Brivanib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2011-08", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2020-09-03", "last_synced_at": "2026-09-11T20:51:36.693Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01367275" }, { "nct_id": "NCT00633789", "title": "Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-small Cell Lung Cancer", "Transitional Cell Carcinoma", "Soft Tissue Sarcoma", "Gastric/Esophageal Adenocarcinoma", "Pancreatic Cancer Including Ampulla of Vater" ], "interventions": [ { "name": "brivanib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 597, "start_date": "2008-06", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-11T20:51:36.693Z", "location_count": 6, "location_summary": "Chicago, Illinois • Evanston, Illinois • Baltimore, Maryland + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00633789" }, { "nct_id": "NCT01253668", "title": "Brivanib Metastatic Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Brivanib alaninate", "type": "DRUG" }, { "name": "Polymerase chain reaction", "type": "GENETIC" }, { "name": "Iodine I 124 chimeric monoclonal antibody G250", "type": "OTHER" }, { "name": "Positron emission tomography/computed tomography", "type": "PROCEDURE" }, { "name": "Protein expression analysis", "type": "GENETIC" }, { "name": "Immunohistochemistry", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2011-11", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-09-11T20:51:36.693Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01253668" }, { "nct_id": "NCT00435669", "title": "A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "Brivanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2007-09", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2009-01-22", "last_synced_at": "2026-09-11T20:51:36.693Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00435669" }, { "nct_id": "NCT00825955", "title": "Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "Brivanib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Best Supportive Care", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 587, "start_date": "2009-02-17", "completion_date": "2017-08-25", "has_results": false, "last_update_posted_date": "2019-10-09", "last_synced_at": "2026-09-11T20:51:36.693Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Loma Linda, California + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00825955" } ] }